References
- Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258–271. http://www.ncbi.nlm.nih.gov/pubmed/11921020 . Accessed January 24, 2019. doi: 10.1002/ajh.10062
- Michel M. Classification and therapeutic approaches in autoimmune hemolytic anemia: an update. Expert Rev Hematol. 2011;4(6):607–618. doi:10.1586/ehm.11.60.
- Barcellini W. Immune hemolysis: diagnosis and treatment recommendations. Semin Hematol. 2015;52(4):304–312. doi:10.1053/j.seminhematol.2015.05.001.
- Valent P, Lechner K. Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr. 2008;120(5–6):136–151. doi: 10.1007/s00508-008-0945-1
- Genty I, Michel M, Hermine O, et al. Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases. La Rev Med Interne. 2002;23(11):901–909. http://www.ncbi.nlm.nih.gov/pubmed/12481390 . Accessed March 8, 2019. doi: 10.1016/S0248-8663(02)00688-4
- Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831–1838. doi:10.1182/blood-2010-03-259325.
- Sokol RJ, Hewitt S, Stamps BK. Autoimmune hemolysis: mixed warm and cold antibody type. Acta Haematol. 1983;69(4):266–274. doi:10.1159/000206903.
- Shulman IA, Branch DR, Nelson JM, et al. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA. 1985;253(12):1746–1748. http://www.ncbi.nlm.nih.gov/pubmed/3974053 . Accessed September 10, 2019.9. doi: 10.1001/jama.1985.03350360072021
- Allgood JW, Chaplin H. Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med. 1967;43(2):254–273. http://www.ncbi.nlm.nih.gov/pubmed/6034957 . Accessed January 24, 2019. doi: 10.1016/0002-9343(67)90168-4
- Murphy S, LoBuglio AF. Drug therapy of autoimmune hemolytic anemia. Semin Hematol. 1976;13(4):323–334. http://www.ncbi.nlm.nih.gov/pubmed/1006333. Accessed January 24, 2019.
- Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev. 2008;22(1):17–31. doi:10.1016/j.blre.2007.08.001.
- Crowther M, Chan YLT, Garbett IK, et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood. 2011;118(15):4036–4040. doi:10.1182/blood-2011-05-347708.
- Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547–1554. doi:10.3324/haematol.2014.114561.
- Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930–2936. doi:10.1182/blood-2014-06-583021.
- Rattarittamrong E, Eiamprapai P, Tantiworawit A, et al. Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia. Hematology. 2016;21(6):368–374. doi:10.1080/10245332.2016.1138621.
- Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89(9):E150–E155. doi: 10.1002/ajh.23767
- Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. 2017. doi:10.1182/blood-2016-11
- Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. Transfus Med Hemotherapy. 2015;42(5):294–301. doi:10.1159/000438731.
- Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch Surg. 1985;120(5):625–628. http://www.ncbi.nlm.nih.gov/pubmed/3985801. Accessed February 21, 2019. doi: 10.1001/archsurg.1985.01390290099017
- Bonnet S, Guédon A, Ribeil J-A, et al. Indications and outcome of splenectomy in hematologic disease. J Visc Surg. 2017;154(6):421–429. doi:10.1016/j.jviscsurg.2017.06.011.
- Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61(2):98–102. http://www.ncbi.nlm.nih.gov/pubmed/10367787. Accessed February 21, 2019. doi: 10.1002/(SICI)1096-8652(199906)61:2<98::AID-AJH4>3.0.CO;2-G
- Patel NY, Chilsen AM, Mathiason MA, et al. Outcomes and complications after splenectomy for hematologic disorders. Am J Surg. 2012;204(6):1014–1020. doi:10.1016/j.amjsurg.2012.05.030.
- Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. Expert Rev Clin Immunol. 2018;14(10):857–872. doi:10.1080/1744666X.2018.1521722.
- Krauth M-T, Lechner K, Neugebauer EAM, et al. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention–an unresolved issue. Haematologica. 2008;93(8):1227–1232. doi:10.3324/haematol.12682.
- Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124(18):1973–1981. doi:10.1161/CIRCULATIONAHA.110.015008.
- Bisharat N, Omari H, Lavi I, et al. Risk of infection and death among post-splenectomy patients. J Infect. 2001;43(3):182–186. doi:10.1053/jinf.2001.0904.
- Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect. 2001;7(12):657–660. http://www.ncbi.nlm.nih.gov/pubmed/11843905 . Accessed January 24, 2019. doi: 10.1046/j.1198-743x.2001.00355.x
- Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015;14(4):304–313. doi:10.1016/j.autrev.2014.11.014.
- Barcellini W. Current treatment strategies in autoimmune hemolytic disorders. Expert Rev Hematol. 2015;8(5):681–691. doi:10.1586/17474086.2015.1073105.
- Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163(3):393–399. doi:10.1111/bjh.12541.
- Kruatrachue M SS. Autoimmune hemolytic anemias in Thailand. Scan J Haematol. 1977;19(1):61–67. doi: 10.1111/j.1600-0609.1977.tb02719.x
- Dussadee K, Taka O, Thedsawad A, et al. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thail. 2010;93(Suppl. 1):165–170.
- Naithani R, Agrawal N, Mahapatra M, et al. Autoimmune hemolytic anemia in India: clinico-hematological spectrum of 79 cases. Hematology. 2006;11(1):73–76. doi:10.1080/10245330500345587.
- Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre. Br Med J (Clin Res Ed). 1981: 2023–2027. https://www.ncbi.nlm.nih.gov/pubmed/?term=sokol+RJ+autoimmune+haemolysis+865+cases . Accessed February 25, 2019. doi: 10.1136/bmj.282.6281.2023
- Michel M. Warm autoimmune hemolytic anemia: Advances in pathophysiology and treatment. Presse Med. 2014;43(4):e97–e104. doi:10.1016/j.lpm.2014.02.009.
- Lecouffe-Desprets M, Néel A, Graveleau J, et al. Venous thromboembolism related to warm autoimmune hemolytic anemia: a case-control study. Autoimmun Rev. 2015;14(11):1023–1028. doi:10.1016/j.autrev.2015.07.001.
- Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89(4):1121–1132. http://www.ncbi.nlm.nih.gov/pubmed/9028933 . Accessed January 24, 2019.
- Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22(8):727–733. doi:10.1177/1076029615622002.
- Jaime-Pérez JC, Colunga-Pedraza PR, Gómez-Ramírez CD, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol. 2011;90(5):523–527. doi:10.1007/s00277-011-1163-x.